I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M	placebo	6-minute walk test (6MWT) at 6 months	15716	15817	There was no significant change at 6 months (p = .263) in either the 200M-group or placebo (p = .112)
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M	placebo	incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion	12401	12468	No TE-SAEs occurred in any of the three groups in the first 30 days
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M	placebo	incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion	12401	12468	No TE-SAEs occurred in any of the three groups in the first 30 days
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M	placebo	short physical performance battery (SPPB) total score at 6 months	15945	16094	SPPB total score was significantly improved in the 100M-group from baseline to 6 months (median 10.5, IQR 9.0, 12.0 to 12.0, IQR 11.0, 12.0; p = .031
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M	placebo	incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion	12401	12469	No TE-SAEs occurred in any of the three groups in the first 30 days.
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M	placebo	6-minute walk test (6MWT) at 6 months	15716	15818	There was no significant change at 6 months (p = .263) in either the 200M-group or placebo (p = .112).
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M	placebo	6-minute walk test (6MWT) at 6 months	15594	15817	. The 6MWT increased in the 100M-group from baseline to 6 months (345.9 ± 103.4 to 410.7 ± 155.4 m, p = .011; Figure 2A). There was no significant change at 6 months (p = .263) in either the 200M-group or placebo (p = .112)
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M	placebo	6-minute walk test (6MWT) at 6 months	15596	15702	The 6MWT increased in the 100M-group from baseline to 6 months (345.9 ± 103.4 to 410.7 ± 155.4 m, p = .011
I/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M	placebo	incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion	12401	12469	No TE-SAEs occurred in any of the three groups in the first 30 days.
